Drug maker Alkem Laboratories has received approval from capital markets regulator Securities and Exchange Board of India (SEBI) to raise an estimated Rs 1,500-3,500 crore through an initial public offering (IPO). This will be one of the biggest offerings in the pharma space in a long time.
Alkem Laboratories filed the Draft Red Herring Prospectus (DRHP) with SEBI on August 6 for a public issue of its equity shares. The Securities and Exchange Board of India (SEBI) has cleared the proposed initial share sale and gave its final observations on the IPO on October 19.
It has proposed to list its shares on the NSE and BSE. The issue is being managed by Nomura Financial Advisory and Securities (India), Axis Capital, J P Morgan India and Edelweiss Financial Services.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: